Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors
Metrics: HTML 1241 views | ?
Kristy Pilbeam1, Hongbo Wang1, Elizabeth Taras2, Rachel J. Bergerson1, Brianna Ettestad1, Todd DeFor3, Antonella Borgatti4, Daniel A. Vallera2,* and Michael R. Verneris1,*
1Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN 55345, USA
2Radiation Oncology, University of Minnesota, Minneapolis, MN 55345, USA
3Biomedical Statistics, University of Minnesota, Minneapolis, MN 55345, USA
4Veterinary Medicine, University of Minnesota, Minneapolis, MN 55345, USA
*These authors have contributed equally to this work
Michael R. Verneris, email: Michael.Verneris@ucdenver.edu
Keywords: Ewing’s sarcoma, rhabdomyosarcoma, urokinase-type plasminogen activator receptor (uPAR), epidermal growth factor receptor (EGFR), immunotherapy
Received: May 04, 2017 Accepted: August 07, 2017 Published: September 23, 2017
Children with high risk sarcoma have a poor prognosis despite surgical resection, irradiation and chemotherapy. Alternative therapies are urgently needed. Urokinase-type plasminogen activator receptor (uPAR) and epidermal growth factor receptor (EGFR) are surface proteins expressed by some pediatric sarcomas. We show for the first time that a de-immunized bispecific ligand toxin, EGFATFKDEL, directed against EGFR and uPAR, successfully targets pediatric sarcoma. Using flow cytometry, we identified a rhabdomyosarcoma (RMS) cell line, RH30, that expresses both uPAR and EGFR, and a Ewing sarcoma (EWS) cell line, TC-71, that expresses only uPAR. We tested the differential sensitivity of these two sarcoma cell lines to toxin-induced killing, using both in vitro assays and an in vivo murine model. We show that pediatric sarcomas are highly sensitive to EGFATFKDEL (at subnanomolar concentrations) in vitro. In vivo, tumor growth was significantly attenuated after treatment with EGFTFKDEL, compared to untreated controls, in both RH30 and TC-71 tumor bearing mice. In addition, we found that simultaneously targeting both receptors in a dual positive cell line was more effective than targeting a single receptor or antigen, resulting in a greater tumor response, including complete tumor regression in an animal model of bulky disease. Our findings provide support for further exploration of bispecific targeting of pediatric sarcomas with bispecific ligand toxins, such as EGFATFKDEL.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.